艾曲泊帕联合免疫抑制治疗儿童初治重型再生障碍性贫血
该研究为一项试验的儿科亚组分析,纳入40例接受艾曲泊帕(EPAG)联合标准免疫抑制治疗(IST)的初治重型再生障碍性贫血(SAA)患儿,与87例历史对照(仅IST)比较。结论:EPAG联合IST未改善儿童初治SAA结局,不应自动视为儿童标准治疗。
要点
- EPAG组复发趋势更高且EFS显著低于IST alone。
- EPAG在儿童SAA中不应自动视为标准治疗。
核心结论
- 在儿童初治SAA中,艾曲泊帕联合标准IST未改善结局,且复发趋势更高、EFS显著更低。
研究设计与样本
- 试验的儿科亚组分析,纳入40例<18岁接受EPAG联合标准IST的初治SAA患者,与87例历史队列(仅IST)比较。
主要发现
- 年幼儿童缓解率低于青少年。
- EPAG组复发趋势更高,EFS显著低于仅IST组。
临床怎么用
- 儿童初治SAA不应自动将EPAG联合IST视为标准治疗。
局限性
- 为儿科亚组分析,样本量有限(EPAG组40例,历史组87例),非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired severe aplastic anaemia (SAA) has an immune pathogenesis, and immunosuppressive therapy (IST) with anti-thymocyte globulin and cyclosporine is effective therapy. Eltrombopag (EPAG) added to standard IST was associated with higher overall and complete response rates in patients with treatment-naïve SAA compared to a historical IST cohort. We performed a paediatric subgroup analysis of this trial including all patients aged <18 years who received EPAG plus standard IST (n = 40 patients) compared to a historical cohort (n = 87) who received IST alone. Response, relapse, clonal evolution, event-free survival (EFS), and overall survival were assessed. There was no significant difference in either the overall response rate (ORR) or complete response rate at 6 months (ORR 70% in EPAG group, 72% in historical group, P = 0·78). Adults (≥18 years) had a significantly improved ORR of 82% with EPAG compared to 58% historically (P < 0·001). Younger children had lower response rates than did adolescents. The trend towards relapse was higher and EFS significantly lower in children who received EPAG compared to IST alone. Addition of EPAG added to standard IST did not improve outcomes in children with treatment-naïve SAA. EPAG in the paediatric population should not automatically be considered standard of care. Registration: clinicaltrials.gov (NCT01623167).
引用
- Groarke EM, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia. Br J Haematol. 2021. PMID: 33410523. doi:10.1111/bjh.17232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。